Some error occured while loading the Quick View. Please close the Quick View and try reloading the page.
With a new foreword by Nora Volkow, Director of the National Institute on Drug Abuse, this second edition of Office-Based Buprenorphine Treatment of Opioid Use Disorder provides updated information on evidence-based treatment for opioid use disorder (OUD)—an increasingly important topic as the epidemic of opioid misuse and overdose deaths grows in the United States.
Bulleted clinical pearls at the end of each chapter, as well as specific clinical recommendations and detailed case discussions throughout, make it easier for readers to retain knowledge and integrate it into their clinical practice. The guide also features sample documentation and scales, including a treatment contract and a patient consent, that can be used to model documents in practice.
This new edition of Office-Based Buprenorphine Treatment has been updated to reflect DSM-5 language, and two additional chapters have been included: one that addresses other pharmacotherapies useful in treating OUD, including methadone and naltrexone, and another that discusses OUD treatment specifically with regard to women's health and pregnancy.
Among the numerous other revisions included in the second edition are the following:
• Information about new formulations of buprenorphine
• A discussion of the Comprehensive Addiction and Recovery Act (CARA)
• Changes to induction and maintenance target doses and recommendations for home inductions
• Information on diversion control plans
• Advice for working with Alcoholics Anonymous and Narcotics Anonymous
• A discussion on integrating buprenorphine into residential and inpatient opioid treatment programs
Written in a jargon-free style that does not require expertise in substance use disorder treatment, Office-Based Buprenorphine Treatment of Opioid Use Disorder is an accessible, indispensable reference for primary care physicians, psychiatrists, nurse practitioners, residents, medical students, and anyone with an interest in learning about and prescribing buprenorphine.
This book provides good clinical guidance for those interested in offering medication-assisted treatments for this patient population. An added bonus is that this book can be used to complete the qualifying training required for the buprenorphine waiver.
— Michael Easton, M.D.
John A. Renner Jr., M.D., is Professor of Psychiatry at Boston University School of Medicine and Associate Chief of Psychiatry of the VA Boston Healthcare System in Boston, Massachusetts.
Petros Levounis, M.D., M.A., is Professor and Chair of the Department of Psychiatry at Rutgers New Jersey Medical School and Chief of Service at University Hospital in Newark, New Jersey.
Anna T. LaRose, M.D., is Instructor in Psychiatry at Boston University Medical School and Staff Psychiatrist at the VA Boston Healthcare System in Boston, Massachusetts.
Contributors
Dedication
Foreword
Chapter 1. Opioid Use Disorder in America: History and Overview
Chapter 2. General Opioid Pharmacology
Chapter 3. Efficacy and Safety of Buprenorphine
Chapter 4. Patient Assessment
Chapter 5. Clinical Use of Buprenorphine
Chapter 6. Buprenorphine Treatment in Office-Based Settings
Chapter 7. Psychosocial and Supportive Treatment
Chapter 8. Referral, Logistics, and Diversion
Chapter 9. Methadone, Naltrexone, and Naloxone
Chapter 10. Psychiatric Comorbidity
Chapter 11. Medical Comorbidity
Chapter 12. Acute and Chronic Pain
Chapter 13. Opioid Use by Adolescents
Chapter 14. Women's Health and Pregnancy
Chapter 15. Comments on the Case Vignettes
Appendix 1: Useful Web Sites and Recommended Readings
Appendix 2: Buprenorphine and Office-Based Treatment of Opioid Use Disorder Supplemental Materials
Index